SpyGlass Pharma, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SGP research report →
Range $37 – $39
Price Chart
About the company
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT).
- CEO
- Patrick H. Mooney
- IPO
- 2026
- Employees
- 76
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on SGP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $828.48M
- P/E
- -14.93
- PEG
- 0.11
- P/S
- 0.00
- P/B
- 3.57
- EV/EBITDA
- -10.39
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -75.64%
- ROIC
- -26.54%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-612,000+0.0%
- Op Income
- $-41,449,000
- Net Income
- $-39,869,000+0.0%
- EPS
- $-1.25+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $32.44
- 52W Low
- $17.06
- 50D MA
- $26.20
- 200D MA
- $24.06
- Beta
- -0.89
- RSI (14)
- 40
- Avg Volume
- 112.73K
No earnings-call transcripts are available for SGP yet.
- Free Float
- 41.7%
- Shares Outstanding
- 33.43M
- Float Shares
- 13.95M
of shares held by institutions
35 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 8.02M | 0 |
| Nea Management Company, LLC | 7.39M | 0 |
| Sands Capital Ventures, LLC | 2.50M | 0 |
| Samsara Biocapital, LLC | 2.11M | 0 |
| Blackrock, Inc. | 711.71K | ▲ 566.97K |
| Price T Rowe Associates Inc | 674.14K | ▼ 30.30K |
| Vestal Point Capital, LP | 670.00K | ▲ 3.24K |
| Jpmorgan Chase & Co | 629.74K | ▲ 52.63K |
| Deerfield Management Company, L.P. (Series C) | 550.00K | 0 |
| Millennium Management LLC | 507.26K | ▲ 38.46K |
| Abrdn PLC | 493.08K | ▲ 272.62K |
| Vanguard Capital Management LLC | 434.42K | ▼ 390 |
Held by 121 ETFs
Biggest fund positions in SGP by dollar value.
Our SGP coverage
Recent articles, reports, and earnings notes.
No research on SGP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SGP report →SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
globenewswire.com · Oct 1
SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
seekingalpha.com · Sep 10
SpyGlass Pharma to Participate in Upcoming Investor Conferences
globenewswire.com · Sep 2
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More
247wallst.com · Aug 14
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com · Aug 6
Spyglass Pharma (NASDAQ:SGP) Shares Gap Up – Still a Buy?
defenseworld.net · Jul 26
Affinity Asset Advisors LLC Buys Shares of 250,000 Spyglass Pharma, Inc. $SGP
defenseworld.net · Jul 25
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
globenewswire.com · Jun 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.